CA2506686A1 - Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants - Google Patents

Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA2506686A1
CA2506686A1 CA002506686A CA2506686A CA2506686A1 CA 2506686 A1 CA2506686 A1 CA 2506686A1 CA 002506686 A CA002506686 A CA 002506686A CA 2506686 A CA2506686 A CA 2506686A CA 2506686 A1 CA2506686 A1 CA 2506686A1
Authority
CA
Canada
Prior art keywords
cct6
assay
agent
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506686A
Other languages
English (en)
Inventor
Albert K. Tai
Chunyan Song
Michael Martin Ollmann
Lucile A. Gillett
Kim Lickteig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506686A1 publication Critical patent/CA2506686A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Des gènes CCT6 humains sont identifiés comme modulateurs de la voie RB et sont, en conséquence, des cibles thérapeutiques pour des troubles associés à une fonction RB défectueuse. L'invention concerne des procédés d'identification de modulateurs de RB, comprenant la sélection d'agents modulant l'activité de CCT6.
CA002506686A 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants Abandoned CA2506686A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US60/428,872 2002-11-25
PCT/US2003/037548 WO2004048541A2 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Publications (1)

Publication Number Publication Date
CA2506686A1 true CA2506686A1 (fr) 2004-06-10

Family

ID=32393472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506686A Abandoned CA2506686A1 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Country Status (5)

Country Link
EP (1) EP1578945A4 (fr)
JP (1) JP4646631B2 (fr)
AU (2) AU2003294501B2 (fr)
CA (1) CA2506686A1 (fr)
WO (2) WO2004048536A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263403B2 (en) 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
GB9608937D0 (en) * 1996-04-29 1996-07-03 Cancer Res Campaign Tech Screening methods for therapeutics and peptides used in the screen
EP1054969A2 (fr) * 1998-02-12 2000-11-29 Curagen Corporation Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

Also Published As

Publication number Publication date
WO2004048536A3 (fr) 2004-08-19
AU2003294499A8 (en) 2004-06-18
WO2004048536A2 (fr) 2004-06-10
AU2003294501A1 (en) 2004-06-18
WO2004048541A2 (fr) 2004-06-10
EP1578945A4 (fr) 2006-09-27
WO2004048541A3 (fr) 2005-08-18
AU2003294499A1 (en) 2004-06-18
JP2006507005A (ja) 2006-03-02
AU2003294501B2 (en) 2010-05-13
EP1578945A2 (fr) 2005-09-28
JP4646631B2 (ja) 2011-03-09

Similar Documents

Publication Publication Date Title
US20030165966A1 (en) MSRAs as modifiers of the p53 pathway and methods of use
US20060084063A1 (en) Rabs as modifiers of the p53 pathway and methods of use
US20120107827A1 (en) PSMCs As Modifiers of the RB Pathway and Methods of Use
CA2497793A1 (fr) Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes
AU2003294501B2 (en) CCT6S as modifiers of the RB pathway and methods of use
WO2004005483A2 (fr) Adcy3s modificateurs de la voie p21 et methodes d'utilisation
US20070141648A1 (en) Flj10607 as modifier of the axin pathway and methods of use
CA2535897A1 (fr) Sulf utilises comme modificateurs de la voie beta-catenine et procedes associes
CA2513668A1 (fr) Dyrks utilises comme modificateurs des voies d'apc et d'axin et leurs procedes d'utilisation
WO2004015071A2 (fr) Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
US20060063710A1 (en) Flj20647s as modifiers of the p21 pathway and methods of use
WO2005052131A2 (fr) Gene c140rf35 utilise en tant que modificateur de la voie de passage de la $g(b)-catenine et methodes d'utilisation correspondantes
CA2513615A1 (fr) Genes facl utilises comme modificateurs de la voie du retinoblastome (rb) et technique d'utilisation
WO2003052066A2 (fr) Klcs utilises en tant que genes modificateurs de la voie p53 et procedes d'utilisation correspondant
WO2005073724A1 (fr) Mbcats utiles comme genes modificateurs du mecanisme d'action de la beta-catenine et leurs methodes d'utilisation
WO2005003306A2 (fr) Sppls utilises en tant que modificateurs de la voie p53 et procedes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead